Evidence map›Paper›PMID 40717954›Full record

ArticleFrontiers in public health2025

Comparing the trends of cancer burden attributed to high BMI in China and globally from 1990 to 2021, with multi-model prediction to 2036.

Nanting Chen, Lingzhi Xing, Fengyun Xiang, Chengmiao Li, Letai Li, Jingsong Cheng, Yangfan Yu, Yubowen Gong, Xiao Liu, Fangjiao Xie and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nanting Chen *The Second Clinical College, Chongqing Medical University, Chongqing, China.
Lingzhi Xing *The Center of Experimental Teaching Management, Chongqing Medical University, Chongqing, China.
Fengyun XiangThe Center of Experimental Teaching Management, Chongqing Medical University, Chongqing, China.
Chengmiao LiThe Second Clinical College, Chongqing Medical University, Chongqing, China.
Letai LiThe First Clinical College, Chongqing Medical University, Chongqing, China.
Jingsong ChengThe Second Clinical College, Chongqing Medical University, Chongqing, China.
Yangfan YuThe Second Clinical College, Chongqing Medical University, Chongqing, China.
Yubowen GongThe First Clinical College, Chongqing Medical University, Chongqing, China.
Xiao LiuKey Laboratory, Tongliang District People's Hospital, Chongqing, China.
Fangjiao XieThe Department of Clinical Laboratory, The People's Hospital of Rongchang District, Chongqing, China.
Ling ChenThe Center of Experimental Teaching Management, Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: High body mass index (BMI) has been identified as a significant contributor to cancers. However, details regarding the evolution of the cancer burden attributable to high BMI in China have not been available. With the epidemic of high BMI among Chinese recent years, it's essential to evaluate the disease burden of cancer associated with high BMI to guide disease interventions and enhance public health. This study aimed to evaluate the burden of high BMI-attributed cancer in China from 1990 to 2021 and compare it with global trends. Methods: The temporal trends of high BMI-attributed cancer were assessed using annual percentage change (APC) and overall percentage change. Decomposition and age-period-cohort analyses were conducted to identify influential factors, while future trends were projected with the Bayesian age-period-cohort (BAPC), auto-regressive moving average model (ARIMA), and exponential smoothing model (ETS). Results: In China, the age-standardized mortality rate (ASMR) and age-standardized disability-adjusted life-years rate (ASDR) for high BMI-attributed cancer increased to 2.81 (95% UI: 1.20-4.76)/10 Conclusions: Although China's current high BMI-attributed cancer burden remains below the global average, it is increasing at a substantial rate and is expected to continue increasing rapidly. Targeted prevention strategies tailored to age and the latest high BMI-attributed cancer spectrum are urgently needed to mitigate this growing public health concern in China.

Indexed as

Body Mass IndexCost of IllnessGlobal HealthNeoplasmsAdultAgedBayes TheoremChinaDisability-Adjusted Life YearsFemaleHumansMaleMiddle Agedage-standardized disability-adjusted life-years rateage-standardized mortality ratecancersChinaglobal burden of diseasehigh BMI

Identifiers

PMID40717954
PMCPMC12289581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.